1. Show article details.

    Morning Brief: Top Financial Stories Dominating on Monday, June 13

    Benzinga – 8:05 AM ET 06/13/2022

    CNBC JPMorgan Remains Bullish On Alibaba And Other Chinese Stocks - Here's Why More Pain Ahead For Ethereum?

  2. Show article details.

    Moderna's COVID-19 Vaccine Shows Safety, Effectiveness For Children Under 17 Years

    Benzinga – 7:36 AM ET 06/13/2022

    Moderna's COVID-19 Vaccine Shows Safety, Effectiveness For Children Under 17 Years

  3. Show article details.

    Pfizer/BioNTech's Three-Dose COVID-19 Vaccine Safe, Effective In Younger Kids

    Benzinga – 6:51 AM ET 06/13/2022

    According to the FDA briefing document, Pfizer Inc  -BioNTech's SE  COVID-19 vaccines were effective and safe for children aged six months to 4 years. The FDA reviewers said that their evaluation did not reveal any new safety concerns related to using the vaccine in young children. The FDA analysis of data from Pfizer's trial was published ahead of a June 14-15 meeting of its outside advisers.

  4. Show article details.

    Sanofi-GSK's Next-Gen COVID-19 Booster Shows Potential Against Variants Of Concern

    Benzinga – 6:47 AM ET 06/13/2022

    Sanofi-GSK's Next-Gen COVID-19 Booster Shows Potential Against Variants Of Concern

  5. Show article details.

    BioNTech Whale Trades For June 10

    Benzinga – 4:38 PM ET 06/10/2022

    A whale with a lot of money to spend has taken a noticeably bearish stance on BioNTech. Looking at options history for BioNTech we detected 10 strange trades. If we consider the specifics of each trade, it is accurate to state that 30% of the investors opened trades with bullish expectations and 70% with bearish.

  6. Show article details.

    BioNTech to Provide an Update on Manufacturing and Development Plans of mRNA Vaccines in Africa

    GlobeNewswire – 8:31 AM ET 06/09/2022

    MAINZ, Germany, June 9, 2022 — BioNTech SE (BNTX) will welcome its African partners for the first time on the African continent and provide an update on the joint establishment of mRNA manufacturing facilities and vaccine development plans.

  7. Show article details.

    Morning Brief: Top Financial Stories Dominating on Thursday, June 9

    Benzinga – 8:27 AM ET 06/09/2022

    Reuters Blackstone Closes In Crown Bid After Australia Approvals: Reuters United States Helps To Keep Taiwanese Warships In Service State Street Might Tap Credit Suisse As Takeover Interest Wall Street Journal US Schedules Covid-19 Vaccines For Children Below Five Years Bloomberg Here's Why Alibaba Shares Are Trading Lower Premarket After Brief Jump India's Apollo Global, Reliance Make a Bindin...

  8. Show article details.

    US Schedules Covid-19 Vaccines For Children Below Five Years

    Benzinga – 7:51 AM ET 06/09/2022

    US Schedules Covid-19 Vaccines For Children Below Five Years

  9. Show article details.

    HC Wainwright Says Non-mRNA COVID-19 Option Underappreciated

    Benzinga – 2:57 PM ET 06/08/2022

    HC Wainwright Says Non-mRNA COVID-19 Option Underappreciated

  10. Show article details.

    What's Next For Novavax Stock As COVID Vaccine Clears Key Hurdle In US

    Benzinga – 7:58 AM ET 06/08/2022

    After last week's scare stirred by the release of the Food And Drug Administration's briefing documents, Novavax  can now heave a sigh of relief.

  11. Show article details.

    COVID-19 Vaccine Patent Waiver Expected Soon, Says WTO Head: Reuters

    Benzinga – 7:21 AM ET 06/08/2022

    COVID-19 Vaccine Patent Waiver Expected Soon, Says WTO Head: Reuters

  12. Show article details.

    Pfizer To Boost Production Of Oral COVID-19 Pill With $120M Michigan Investment

    Benzinga – 4:18 AM ET 06/07/2022

    Pfizer, Inc. is upping its commitment to manufacture its oral COVID-19 pill Paxlovid in the United States. What Happened: Pfizer will invest an incremental $120 million at its Kalamazoo, Michigan facility to augment production of Paxlovid, the pharma giant said in a statement late Monday.

  13. Show article details.

    Short Volatility Alert: BioNTech SE

    Benzinga – 9:49 AM ET 06/06/2022

    On Friday, shares of BioNTech SE experienced volatile short activity. The overall sentiment for BNTX has been Bearish. The signal from the volatility alert is trending Bullish. Therefore, the recommendation is to Decrease Short Exposure.

  14. Show article details.

    Early Data Shows BioNTech's Personalized Therapy Safe In Pancreatic Cancer Patients

    Benzinga – 7:11 AM ET 06/06/2022

    Early Data Shows BioNTech's Personalized Therapy Safe In Pancreatic Cancer Patients

  15. Show article details.

    Positive Phase 1 Data from mRNA-based Individualized Neoantigen Specific Immunotherapy in Patients with Resected Pancreatic Cancer presented at ASCO

    GlobeNewswire – 12:30 PM ET 06/05/2022

    MAINZ, Germany and CHICAGO, June 5, 2022 – BioNTech SE (BNTX) today announced initial data from an ongoing investigator-initiated first-in-human Phase 1 study evaluating the safety and tolerability of the mRNA-based individualized neoantigen specific immunotherapy autogene cevumeran in combination with anti-PD-L1 immune checkpoint inhibitor atezolizumab and chemotherapy in patients with resected pancr...

  16. Show article details.

    Morning Brief: Top Financial Stories Dominating on Thursday, June 2

    Benzinga – 8:01 AM ET 06/02/2022

    Reuters China Will Lose Ability To Access Amazon's Kindle E-Book Store From 2023 Toshiba Gets Privatization Proposals - Guess How Many Are Interested Delta, United Airlines Positive On Post-Pandemic Spending Biden Visit Might Push For Saudi Arabia And OPEC To Make Up For Russian Oil Loss Wall Street Journal Pfizer Seeks FDA Approval For Three Covid Vaccine Doses For Children Below Five Bloomber...

  17. Show article details.

    Pfizer Seeks FDA Approval For Three Covid Vaccine Doses For Children Below Five

    Benzinga – 7:08 AM ET 06/02/2022

    Pfizer Seeks FDA Approval For Three Covid Vaccine Doses For Children Below Five

  18. Show article details.

    Voting Results from BioNTech’s Annual General Meeting 2022

    GlobeNewswire – 1:15 PM ET 06/01/2022

    MAINZ, GERMANY, June 1, 2022 — At the Annual General Meeting of BioNTech SE (BNTX) held today, June 1, 2022, shareholders voted to reappoint Helmut Jeggle as a member of the Supervisory Board with a majority of 96.44 per cent. In addition, the shareholders passed the proposal of the Management Board and Supervisory Board and resolved to pay a special cash dividend of €2.00 per ordinary share.

  19. Show article details.

    Jim Cramer Shares His Opinion On Roblox, Century Aluminum And More

    Benzinga – 8:03 AM ET 06/01/2022

    On CNBC's "Mad Money Lightning Round," Jim Cramer said he can't recommend Roblox Corp as it is not making money. When asked about Novavax, Inc. , he said, "We have Pfizer Inc. and we have BioNTech SE , and that's what we needed."

  20. Show article details.

    Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates

    Benzinga – 3:42 PM ET 05/31/2022

    May turned out to be a month of mixed fortunes as far as regulatory reviews are concerned. Among the companies that received the FDA's greenlight were Phathom Pharmaceuticals, Inc. , Bristol-Myers Squibb Company and Novartis AG . On the other hand, Verrica Pharmaceuticals Inc.'s viral skin infection treatment candidate was rejected by the regulator for the third time.

Page:

Today's and Upcoming Events

  • Nov
    07

    BNTX to announce Q3 earnings (Confirmed)

Past Events (last 90 days)

  • Aug
    08

    BNTX announced Q2 earnings.

  • Jun
    02

    BNTX ex-Dividend for $2.13 on 06/02/2022

    • Announce Date: 04/27/2022
    • Record Date: 06/03/2022
    • Pay Date: 06/17/2022
Data provided by Thomson Reuters © 2022

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.